Journal of Medicinal Chemistry p. 642 - 646 (1991)
Update date:2022-08-05
Topics:
Flouret
Brieher
Mahan
We prepared nine analogues (1-9) of MCPA-D-Phe-Phe-Ile-Asn-Cys-Pro-Arg-Gly-NH2, [MCPA1,D-Phe2,Phe3, Ile4, Arg8]oxytocin (MCPA = β-mercapto-β,β-pentamethylenepropionic acid), a potent antagonist of the rat uterotonic action of oxytocin (OT). We replaced D-Phe with D-Trp and made [MCPA1,D-Trp2,Phe3,Ile4,Arg8]OT (1), which had OT pA2 of 7.51, somewhat higher than that of the D-Phe2 antagonist which has OT pA2 = 7.35 in our rat uterotonic assay. Both compounds are equipotent as antagonists of [Arg8]vasopressin in the rat antidiuretic assay, with pA2 = 8.1. Other substitutions gave [MCPA1,D-Trp2,4-Cl-Phe3,Ile4,Arg8]OT (2), OT pA2 7.44; [MCPA1,D-Trp2,Phe3,Ile4,3,4-dehydro-Pro7,Arg8]OT (3), OT pA2 = 7.42; [MCPA1,D-Trp2,Phe3,Arg8]OT (4), OT pA2 = 7.58; [MCPA1,D-Trp2,Phe3,Arg8,Gly9-NHEt]OT (5), OT pA2 = 7.49; [MCPA1,D-Trp2,Ile4,Arg8]OT (6), OT pA2 = 7.46; [MCPA1,D-Trp2,Val4,Arg8]OT (7), OT pA2 = 7.58; [MCPA1,D-Trp2,Thr4,Arg8]OT (8), pA2 = 7.48; and finally, [MCPA1,D-Trp2,Arg8]OT (9), which was a more potent and more selective OT antagonist, with OT pA2 = 7.77 in the uterotonic assay and ADH pA2 < 5.9 in the antidiuretic assay and hence is an important lead for the design of OT antagonists.
View MoreWuhan Silworld Chemical Co.,Ltd
website:http://www.silworldchemical.com
Contact:+86-27-85613400
Address:No.198 jiangjun Road, Wuhan,China 430033
Changde Yungang Biotechnology Co., Ltd
website:http://www.cdyg.com
Contact:+86-736-7391178
Address:Qiaonan Industrial Park, Changde City, Hunan Province
Contact:+86-(0)21-3770 9035
Address:Room 301, Building 2, Meijiabang Road 1508, Shanghai China
Nanjing distinctions Medical Technology Co., Ltd.(expird)
Contact:+86-15996203785 13914714059
Address:nanjing,jiangsu , China
Golden Union Agrochemical Import and Export Co., Ltd.
Contact:86-755-23910527
Address:Room 1106, Tower 3A, Excellence Century Center, Futian District, Shenzhen, China
Doi:10.1021/ja110405q
(2011)Doi:10.1021/ja203660r
(2011)Doi:10.1007/s10593-011-0696-1
(2011)Doi:10.1016/S0040-4039(99)00360-3
(1999)Doi:10.1002/adfm.201002502
(2011)Doi:10.1039/c1cc11176k
(2011)